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Leukocytes are critical effectors of inflammation and tumor biol-
ogy. Chemokine-like factors produced by such inflammatory sites
are key mediators of tumor growth that activate leukocytic recruit-
ment and tumor infiltration and suppress immune surveillance.
Here we report that the endocrine peptide hormone, relaxin, is a
regulator of leukocyte biology with properties important in recruit-
ment to sites of inflammation. This study uses the human mono-
cytic cell line THP-1 and normal human peripheral bloodmononu-
clear cells to define a novel role for relaxin in regulation of leukocyte
adhesion andmigration. Our studies indicate that relaxin promotes
adenylate cyclase activation, substrate adhesion, and migratory
capacity of mononuclear leukocytes through a relaxin receptor
LGR7-dependent mechanism. Relaxin-stimulated cAMP accumu-
lation was observed to occur primarily in non-adherent cells.
Relaxin stimulation results in increased substrate adhesion and
increased migratory activity of leukocytes. In addition, relaxin-
stimulated substrate adhesion resulted in enhanced chemotaxis to
monocyte chemoattractant protein-1. These responses in THP-1
andperipheral bloodmononuclear cells are relaxindose-dependent
and proportional to cAMP accumulation. We further demonstrate
that LGR7 is critical formediating these biological responses by use
of RNA interference lentiviral short hairpin constructs. In sum-
mary, we provide evidence that relaxin is a novel leukocyte stimula-
tory agent with properties affecting adhesion and chemomigration.
Complex interactions between tumor cells and the immune system
regulate disease progression by stimulating cell proliferation, neovascu-
larization, tissue remodeling, and metastasis or by inhibiting the host
anti-tumor immune response (1). However, the factors produced by
tumor cells that affect their immune surveillance remain to be fully
elucidated. The insulin-related peptide hormone, relaxin, possesses key
features required of a tumor-derived factor capable of affecting malig-
nant progression, and its emerging role as a putative mediator of tumor
progression has been recently reviewed (2). In humans, relaxin is
encoded by three genes designated H1, H2, and H3 (3). Functionally,
relaxin is classically described to improve blood supply to multiple
organs including the uterus, mammary gland, lung, and heart (4).
Relaxin is also known to increase matrix metalloproteinase expression,
resulting in collagen turnover of reproductive tissues and in models of
fibrosis, and is responsible for lengthening of the interpubic ligament
during delivery (3–5).
A role for relaxin in cancer progression was first suggested 38 years
ago by studies indicating that carcinogen-fed rats experienced substan-
tially enhanced mammary tumor growth when co-treated with relaxin
several weeks later (6). More recently, relaxin has been shown to sup-
port growth and invasiveness of breast cancer cells (7, 8), and elevated
relaxin serum levels are positively correlated with breast cancer metas-
tases (9). Relaxin immunostaining has been demonstrated in epithelial
and myoepithelial cells of normal and cancerous breast tissue (10), and
significantly higher levels of relaxin staining occur in neoplastic breast
tissues as compared with normal breast tissue (11). Similarly, relaxin is
produced by the normal prostate (12–16), and expressed in prostate
cancer cell lines LNCaP, DU145, and PC3 (17, 18). Relaxin has been
implicated in increased tumor growth and angiogenesis of PC3 prostate
xenografts (19), whereas we have found that H2 relaxin expression is
up-regulated in LNCaP cells undergoing neuroendocrine differentia-
tion (20). Together, these studies strongly implicate relaxin in breast
and prostate cancer progression. Relaxin has been attributed with reg-
ulation of several intermediary responses or intracellular signaling
events in a variety of cell types. These include cAMP, protein kinase A
(21–27), mitogen-activated protein kinase, cAMP-response element-
binding protein (28), tyrosine phosphorylation (22, 29), nitric-oxide
synthase activation (30–38), and calcium influx (39). These intermedi-
ary signaling events are then implicated in the up-regulation of matrix
metalloproteinases (29, 40–43), epidermal growth factor (44), insulin-
like growth factor (45, 46), insulin-like growth factor-binding proteins
(47), vascular endothelial growth factor (28, 43, 48), and guanylyl cyclase
activation (32, 33, 35). In inflammatory wound sites relaxin also induces
vascular endothelial growth factor and basic fibroblast growth factor
production in macrophages (48). Prevailing questions are whether the
ability of tumors to secrete relaxin affects the surrounding stromal and
endothelial cells or hematopoietic cells and whether relaxin can stimu-
late and/or recruit these cells to produce factors that promote tumor
survival and growth.
Here we demonstrate that relaxin activates adenylate cyclase, pro-
motes substrate adhesion, and proportionally enhances migratory
capacity of mononuclear leukocytes in a relaxin receptor LGR7-
dependentmechanism. Relaxin-stimulated cAMP accumulation occurs
primarily in non-adherent cells, and this responsiveness is lost once the
cells have adhered to a substrate. Relaxin alone can promote migration
of leukocytes and can also enhance their monocyte chemoattractant
protein-1 (MCP-1)2 migratory response. These enhanced migratory
responses may be a result of relaxin-mediated substrate adhesion in
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these cells. We also describe for the first time that relaxin can dose-de-
pendently stimulate cAMP accumulation in peripheral blood mononu-
clear cells (PBMC) and that this response is proportional to relaxin-
stimulated adhesion and migratory activity. We further demonstrate
that LGR7 is critical for mediating these biological responses by use of
RNA interference lentiviral short hairpin constructs. These results
implicate relaxin as a novel stimulator of leukocyte recruitment.
EXPERIMENTAL PROCEDURES
Cell Culture—PBMC were isolated from fresh whole blood obtained
from healthy male and female volunteers by density gradient sedimen-
tation in Histopaque (Sigma) according to the manufacturer’s instruc-
tions. PBMC were washed twice in phosphate-buffered saline, resus-
pended in RPMI (Invitrogen), and used immediately in subsequent
assays. THP-1 cells (ATCC)were cultured in RPMI and 10% fetal bovine
serum. All THP-1 cell experiments were performed with cells cultured
less than 15 passages that were serum-starved overnight before
treatments.
Production of Recombinant THP-1 Clonal Populations—Stably
infected THP-1 populations were generated by lentiviral infection, sta-
ble integration, and expression of short hairpin interfering RNA
(shRNA) sequence targeting LGR7 (LGR7 GenBankTM accession num-
ber NM_021634). shRNA target sequences of LGR7 were selected
according to previously established guidelines (49, 50), and complemen-
tary oligonucleotides were synthesized, annealed, and ligated into the
pSHAG-1 vector backbone (Cold Spring Harbor Laboratory) (49).
Recombination reactions (Gateway, Invitrogen) were performed to
transfer the target sequences into the Gateway-modified pHR-CMV-
eGFP lentiviral vector (51). 10 g of this recombinant vector was co-
transfected with 7.5 g of the packaging plasmid pCMV-gag-pol
(R8.2) and 2.5 g of the VSV-G-expressing envelope plasmid pMD.G
into HEK293T cells (51–53) using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Virus-containing condi-
tioned media was collected every 24 h for 2 days, filtered through
2.0-m pores (Millipore), and immediately used to infect THP-1 cells,
which were subsequently sorted by flow cytometry to obtain the
enhanced green fluorescent protein tag expression approaching 100%.
Of the six shRNA targets created (Supplemental Fig. 1), two, L7–274
(5-CACCTGAATGTTTGGTCGGTTCTGTGCCAG-3) and L7–917
(5-GATTGAAAATCTTCCACCGCTTATATTCAA-3), which effec-
tively suppressed LGR7 expression in THP-1 cells, are described in
these studies.
cAMP Assays—5  105 cells were treated with 6 His-tagged recom-
binant human H2 relaxin (RLXH) (20) at 0 and 0.0013, 0.0025, 0.005,
0.01, 0.02, or 0.04 ng/ml or forskolin (FSK, 10 M) and isobutylmethyl-
xanthine (IBMX, 50 M) for 30 min (relaxin H2 GenBankTM accession
number NM_134441). To control for the RLXH vehicle, all samples
were treated with the volumetric equivalent of the nickel column elu-
tion buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, and
0.05% Tween 20, pH 8.0) as previously described (20). Non-adhered
cells were collected from the media by centrifugation and resuspended
in lysis buffer (Biotrak ELISA kit, Amersham Biosciences). For analysis
of the total population cAMP response, the remaining adhered cells
were lysed by pooling with the lysis of the corresponding non-adhered
cells. For analysis of THP-1 subpopulations, adhered and non-adhered
cells were collected as above and passively lysed separately. Adenylate
cyclase activation was measured by competitive cAMP enzyme-linked
immunosorbent assay (Biotrak ELISA kit, Amersham Biosciences) and
normalized to cell equivalents by protein content (BCA assay, Pierce)
according to the manufacturer’s instructions and expressed as fmol of
cAMP/g of cellular protein.
Cell Adhesion and Migration Assays—For adhesion assays, 5  105
cells were seeded into wells of 24-well tissue culture dishes and left
untreated or treated with RLXH (0.02 ng/ml) or phorbol 12-myristate
13-acetate (PMA, 50 ng/ml) and incubated for 24 h at 37 °C. Non-
adhered cells were removed by decanting and washing the plates three
times with RPMImedia. Formigration assays, 5 105 cells were seeded
in the upper chamber of 24-well 5-m transwell cell culture inserts
(Costar). Cells were treated with RLXH (0.02 ng/ml), GF109203X (2
M), FSK (10 M), and/or MCP-1 (10, 25, or 50 ng/ml). All samples not
treated with RLXH received an equivalent volume of the RLXH vehicle
unless otherwise stated. Migration on uncoated transwells was per-
formed for 24 h at 37 °C, and migration on laminin-coated transwells
was performed for 3 h at 37 °C. The number of adhered ormigrated cells
was determined by CyQuant DNA binding fluorescence (C-7026,
Molecular Probes, Invitrogen) (54). Relative fluorescence was detected
at 485-nmexcitation and 527-nmemission by plate reading fluorometer
(Fluoroskan Accent FL, ThermoLabsystems) and standardized for cell
number. Total and percent adhered or migrated cells were calculated
for each assay, and pooled results are expressed as adhesion index or
migration index, respectively, normalized to cell number of untreated
controls.
Real Time PCR Analysis—LGR7 mRNA expression of parental and
shRNA-expressing THP-1 cells was determined from cells under nor-
mal culture conditions. Total RNA was isolated using TRIzol reagent
(Invitrogen), DNase-treated (Invitrogen) and used to generate single-
stranded cDNAs using Superscript first-strand synthesis system
(Invitrogen) according to the manufacturer’s instructions. RNA (2 g)
was primed for cDNA synthesis using a random hexamer primer (0.5
g/l). The comparative CT (threshold cycle) method was used to
measure LGR7mRNA levels under different treatment conditions using
a GeneAmp 5700 Sequence detection system and the GeneAmp 5700
SDS software (Applied Biosystems). The LGR7 primers LGR7-Rfp (5-
CCCCTGTGGGAACATCACA-3) and LGR7-Rrp (5-GTTGTCCT-
CATCGGCCTGATT-3) and probe (5-VIC-CTCCTGCACTGTA-
ACGGTGTGGACGACT-TAMRA-3) were selected using the Primer
Express software Version 1.5 (Applied Biosystems). The probe was
labeled with a VIC/TAMRA quencher/reporter. A region of TATA-
binding protein (TBP) cDNAwas amplified using control primer/probe
kits from Applied Biosystems. Primer verification analysis was per-
formed to ensure the LGR7/TBP primer pairs had equal amplification
efficiencies (data not shown). TBP mRNA was unaffected by lentivirus
infection or shRNA expression and was, therefore, deemed a suitable
control for normalizing the results to total mRNA levels. The real time
PCR reactions were performed using TaqMan Universal PCR Master
Mix (Applied Biosystems) such that the LGR7 and TBP base-line CT
(threshold cycle) ranges were 5–22 and 5–20, respectively. The thresh-
old log values used in the LGR7 and TBP analyses were 0.03–0.05.
Fluorescence-activated Cytometric Analysis—5  105 live cells sus-
pended in 200 l of phosphate-buffered saline were stained for cell
surface LGR7 expression by incubation with 5 g/ml rabbit polyclonal
anti-LGR7 antibody (ab12714, Abcam) for 45min at 4 °C. To correct for
nonspecific IgG background binding to cell surface, a parallel cell ali-
quot was stained with a rabbit IgG antibody against the intracellular
protein, Akt (anti-Akt, 9272, Cell Signaling). After washing with phos-
phate-buffered saline, cells were treated with a 1:200 dilution of donkey
anti-rabbit R-phycoerythrin-conjugated antibody (Jackson Immunore-
search) for 30 min at 4 °C. Cells were washed twice with phosphate-
buffered saline and then immediately analyzed on flow cytometer (Epics
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xl-mcl, Beckman Coulter) with Expo32 software (Beckman Coulter)
and WinMDI software.
Statistical Analysis—Curve fit analysis was performed using Sig-
maPlot graphics software (SPSS) for linear regression (Fig. 2B) or non-
linear, one-site saturation kinetics (Figs. 1A and 3A). Statistical analysis
was performed with JMPIN statistical discovery software (SAS Insti-
tute). Significant differences among treatments were identified by one-
way analysis of variance, and significant differences between multiple
pairs of treatments were identified by multi-sample matched paired
t-tests analyses at a threshold of p 0.05 unless otherwise noted in the
figure legends.
RESULTS
Relaxin Activates Adenylate Cyclase Preferentially in Non-adher-
ent THP-1 Cells—To assess the capacity of relaxin to affect leukocyte
activity, we have generated RLXH (20). Bioactivity of this reagent
purified by nickel column chromatography was assessed by deter-
mining its ability to stimulate adenylate cyclase activity in target
cells. We previously demonstrated that RLXH stimulates adenylate
cyclase activation in LGR7-expressing HEK 293T cells (20). Here we
observed that RLXH stimulates a dose-dependent increase in intra-
cellular cAMP levels in the monocyte/macrophage cell line THP-1
with first order saturation kinetics (r2 0.9614). Intracellular cAMP
levels were significantly elevated above basal levels by as little as 1.3
pg/ml RLXH and saturated at 9-fold over basal levels (276.9 fmol of
cAMP/g of protein) with a calculated half-maximal dose of 6.8
(1.8) pg/ml RLXH 30 min after stimulation (Fig. 1A). These results
are consistent with previous observations for relaxin-mediated
adenylate cyclase activation of THP-1 cells (21, 22, 24) and confirm
that RLXH is a biologically active relaxin source.
THP-1 cells in culture are in equilibrium between adherent and non-
adherent cells, which may represent phenotypic differences with
respect to differentiation or activation state and relaxin responsiveness.
We, therefore, assessed potential differences in adenylate cyclase acti-
vation by RLXH in adherent and non-adherent populations. Although
the non-adherent THP-1 monocyte populations accounted for 65% of
the total cell number, they were responsible for 85% of the cAMP
response to RLXH (Fig. 1B). This comparison suggests that non-adher-
ent THP-1 cells respond preferentially to relaxin and that this relaxin-
FIGURE 1. Relaxin stimulates adenylate cyclase
activation and substrate adhesion of THP-1
cells. A, serum-starved THP-1 cells were plated
into a 24-well tissue culture plate followed imme-
diately by treatment with RLXH (0 and 0.0013,
0.0025, 0.005, 0.01, 0.02, or 0.04 ng/ml) and incu-
bated at 37 °C for 30 min. Non-adhered and
adhered cells were lysed together in the 24-well
plate. Adenylate cyclase activation was expressed
as fmol of intracellular cAMP normalized to g of
whole cell lysate protein. Values represent the
means  S.E. of five independent experiments,
with each sample assayed in quadruplicate. Paired
t test analyses: a, versus untreated p 0.05; b, ver-
sus untreated p 0.001. B, adenylate cyclase acti-
vation in adhered and non-adhered THP-1 cells
was determined in cells treated as in A except that
non-adhered cells were collected and assayed
separately from adhered cells. Non-adhered cells
accounted for 65% of the total cell number as esti-
mated by relative whole cell lysate protein. White
bars, untreated; black bars, Mock; gray bars, RLXH.
Values represent themeans S.E. of six independ-
ent experiments assayed in triplicate. Paired t test
analyses: a, versus respectivemock treatment, p
0.05; b, versus respective untreated, p  0.05;
c, versus RLXH-treated adhered cells, p  0.05.
C, relaxin-stimulated substrate adhesion of THP-1
cells was measured in cells treated with PMA (50
ng/ml), RLXH (0.02 ng/ml), or untreated (vehicle
alone) and incubated at 37 °C for 24 h as described
under “Experimental Procedures.” Substrate adhe-
sion index was calculated as a –fold change of
CyQuant fluorescence normalized to that of the
untreated samples of washed wells. Values repre-
sent themeans S.E. of eight independent exper-
iments assayed in triplicate. Paired t test analyses:
a, versus untreated p 0.01; b, versus RLXH treat-
ment p 0.05.
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induced adenylate cyclase response may be attenuated upon substrate
adhesion.
Relaxin Stimulates Substrate Adhesion of THP-1Cells—Although the
ability of THP-1 cells to respond to relaxin through activation of adeny-
late cyclase and other signaling pathways has been well characterized
(21, 22, 24, 28, 48), any physiological consequence of relaxin stimulation
has remained undetermined. Based on the above observation, we spec-
ulated that relaxin may promote substrate adhesion of non-adherent
monocytic cells. To examine whether relaxin can promote adhesion of
monocytes to tissue culture plastic, untreated THP-1 cells were com-
pared with cells treated with either RLXHor PMA, an agent well known
to promote THP-1 adhesion and macrophage differentiation (55). In a
temporal analysis comparing the number of adherent cells in untreated
and RLXH-stimulated THP-1 cultures, no significant difference in cell
adhesion was observed before 8 h (data not shown). At 24 h RLXH
induced a 1.5-fold increase in THP-1 adhesion above basal levels (from
30 to 45%), whereas PMA stimulated the expected robust adhesion of
80% of the monocytic population (Fig. 1C). These results indicate that
relaxin has the previously uncharacterized property of stimulating
monocyte substrate adhesion.
Relaxin Stimulates Migration of THP-1 Cells—We reasoned that an
increased ability of monocytes to adhere to surfaces may promote or
enhance migratory capacity through transwells in Boyden-chamber
based assays (56, 57). Temporal analysis of THP-1 migration using a
transwell migration assay showed no difference in RLXH-induced
migratory kinetics before 8 h of stimulation (data not shown), but an
increased number of migrated cells could be observed at longer times,
which was optimal at 24 h after stimulation (1.5-fold, Fig. 2A). To deter-
mine whether RLXH can induce directional migration, a checkerboard
analysis was performed inwhich THP-1 cells seeded in the upper cham-
ber were exposed to RLXH in either the lower or upper chamber or in
both chambers (Fig. 2A). At 24 h after treatment, THP-1 cell migration
into the lower chamber was significantly increased in all three RLXH
treatment conditions. THP-1 cells exposed to the greatest concentra-
tion of RLXH (0.02 ng/ml in both chambers) demonstrated an increased
propensity to migrate to the lower chamber (30% of the seeded popula-
tion), 1.5-fold greater than the untreated control (20%). Similarly,
migration of cells exposed to RLXH (0.02 ng/ml)when added to only the
upper (27%) or lower chamber (25%) was enhanced over untreated con-
trols but were indistinguishable from one another. Cells exposed to
FIGURE2.Relaxin stimulatesmigrationofTHP-1
cells.After overnight serumstarvation, THP-1 cells
were seeded in the upper chamber of 24-well
5-m pore transwells followed immediately by
treatment. A, migration into the lower chamber of
the transwell of untreated cells was compared
with that of cells exposed to RLXH (0.02 ng/ml)
added to the upper, the lower, or both chambers
(relaxin checkerboard analysis). Migration of cells
treated with RLXH (0.02 ng/ml) in both chambers
were compared with RLXH-treated cells in the
presence of GF109203X (2 M) or FSK (10 M) in
both chambers. THP-1 migration was also
assessed for cells treatedwithMCP-1 (50 ng/ml) in
the lower chamber in the absence or presence of
either RLXH (0.02 ng/ml) or FSK (10 M) in both
chambers. All samples were incubated at 37 °C for
24 h. Themigration indexwas calculated as a –fold
change of relative CyQuant fluorescence of cells
migrated into the lower chamber normalized to
that of the untreated samples (vehicle alone ()).
Values represent means S.E. of six independent
experiments assayed in triplicate. Paired t test
analyses: a, versus untreated, p  0.05; b, versus
untreated, p 0.01; c, versus RLXH in lower cham-
ber, p  0.05; d, versus MCP-1 in lower chamber,
p 0.01. B, the effect of relaxin treatment on the
MCP-1 chemotactic response was compared in
THP-1 cells stimulated with MCP-1 in the lower
chamber at (0 and 10, 25, or 50 ng/ml) in the
absence (dashed line) or presence (solid line) of
RLXH (0.02 ng/ml) in both chambers. The migra-
tion index was calculated as above, and values are
expressed as the means S.E. from 10 independ-
ent experiments assayed in triplicate. Paired t test
analyses: a, versus untreated, p  0.01; b, versus
untreated, p  0.001; c, versus no RLXH at same
MCP-1 dose, p  0.05; d, versus no RLXH at same
MCP-1 dose, p 0.01.
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RLXH added to only the lower chamber exhibited a reduced migratory
capacity compared with cells exposed to RLXH in both chambers, likely
because of the reduced initial local concentration of RLXH when it is
sourced farther away from the seeding location. These data demon-
strate that although relaxin alone cannot induce directional (chemotac-
tic) migration, it is capable of promoting dose-dependent chemomigra-
tion proportional to its capacity to induce cAMP accumulation and
adhesion.
Relaxin Augments Migration of THP-1 Cells toward MCP-1—Be-
cause of the numerous reports demonstrating that relaxin induced acti-
vation of the adenylate cyclase signaling in multiple cell types (21–27),
we assessed whether this pathway was important in mediating the
RLXH-stimulated migratory response in THP-1 cells. We determined
that relaxin-induced migration can be replicated by the addition of the
adenylate cyclase activator, FSK, and that relaxin-induced migration is
unaffected by the broad spectrum protein kinase C inhibitor,
GF109203X (Fig. 2A). This suggests that relaxin likely induces chemo-
migration through a cAMP-dependent and protein kinase C-independ-
ent pathway. The archetype MCP-1 (58–60) was added to the lower
chamber to confirm the chemotactic responsiveness of THP-1 cells (Fig.
2A). At 24 h, MCP-1 increased migration of THP-1 cells into the lower
chamber almost 3-fold such that 50% of the cells had migrated into the
lower chamber. Intriguingly, we also observed that MCP-1 chemotaxis
was significantly enhancedwhenRLXHwas added to both chambers. In
the presence of RLXH, MCP-1 chemoattraction was increased to
almost 4-fold over basal levels, such that 75% of THP-1 cells had
migrated into the lower chamber. This RLXH-induced augmentation of
MCP-1 chemotaxis was precisely mimicked when MCP-1 treated cells
were co-stimulatedwith FSK (Fig. 2A). These results indicate that relax-
in-induced adenylate cyclase activation provides an important alterna-
tive pathway to enhancemonocyte responsiveness to the protein kinase
C-dependent MCP-1 chemotactic response (61, 62).
To further investigate the capacity of relaxin to augment MCP-1-
mediated chemomigration, we compared the migration of THP-1 cells
to varying concentrations of MCP-1 in the presence or absence of
RLXH (Fig. 2B). THP-1 cell migration was linearly responsive to stim-
ulation with 0–50 ng/ml MCP-1 (r2  0.9943, y intercept  1.0684
(0.0747) migration index (MI), slope  0.0347 (0.0026) MI/ng/ml
MCP-1). We observed that RLXH co-stimulation proportionally
increased THP-1 cell migration by 1.52-fold (0.0227) over that of cells
treated with MCP-1 alone at all MCP-1 concentrations tested (r2 
0.9966, y intercept  1.6268 (0.0869) migration index (MI), slope 
0.0521 (0.0031)MI/ng/mlMCP-1). The consequence of relaxin expo-
sure is that the chemotactic response at maximal MCP-1 dose (50
ng/ml) can be replicated at 2.5 times lower dose ofMCP-1 (20 ng/ml) in
the presence of RLXH (0.02 ng/ml in both chambers). These results
support the notion that relaxin may make the cells more responsive to
MCP-1 at lower doses and that the presence of relaxin can modulate
leukocytic chemomigration toward limiting concentration of chemoat-
tractants such as MCP-1. The cAMP-signaling dependent adhesion
response of the cells to relaxin is complementary to the protein kinase
C-dependent chemomigratory response of the cells to MCP-1, which
may explain the additive augmentation ofmigration observed in RLXH-
and MCP-1-stimulated cells.
Relaxin Activates Adenylate Cyclase, Promotes Adhesion, and
Enhances Migration of Peripheral BloodMononuclear Cells—To exam-
ine the physiological relevance of these experiments in the context of
leukocyte biology, we assessed whether relaxin could regulate similar
responses in PBMC. Although maximal relaxin-induced adenylate
cyclase activity in PBMC was about 15% that observed in comparably
treated THP-1 cells (saturating at 36.72 fmol of cAMP/g of protein), it
nonethelessmirrored the first order dose-dependent saturation kinetics
of RLXH-stimulated THP-1 cells (r2 0.8782). Intracellular cAMP lev-
els in RLXH-stimulated PBMC were significantly elevated above basal
levels by as little as 2.5 pg/ml RLXH and saturated at 5-fold over basal
levels. The calculated half-maximal dose for PBMC of 3.6 (1.7) pg/ml
RLXH at 30 min after stimulation (Fig. 3A) was statistically indistin-
guishable from the corresponding half-maximal RLXH dose calculated
for THP-1 cells described for Fig. 1A.
Also consistent with the response of THP-1 cells, at 24 h RLXH
induced a 1.5-fold increase in adhesion of PBMC to a tissue culture
plastic substrate (from 55 to 85%) that was proportional to their
response to PMA (Fig. 3B). Furthermore, relaxin induced a 1.8-fold
increase in the migratory response of PBMC (from 20 to 35% of seeded
cells; Fig. 3C). This response was approximately half the migratory
response induced by MCP-1 (60% of seeded cells) and is in excellent
agreement with our previous observations in THP-1 cells. Together
these data suggest that relaxin is a key mediator of adenylate cyclase
activation, substrate adhesion, and migratory responses of PBMC.
Short Hairpin Targeting Suppresses LGR7 mRNA and Protein Levels
in THP-1 Cells—To verify that the relaxin receptor, LGR7 (63), was
responsible for mediating relaxin-regulated adenylate cyclase and
chemomigration responses of THP-1 cells, we developed an RNA inter-
ference approach to inhibit LGR7 expression using lentiviral infection,
stable integration, and expression of short hairpin interfering RNA
sequence independently targeting six different regions of LGR7 (Sup-
plemental Fig. 1). Of these six targeted sequences, two proved to be
effective in down-regulating LGR7 expression at themRNAand protein
levels (Figs. 4, A and B, respectively). Using real time PCR analysis, we
found that LGR7mRNA expression was substantially impaired (3-fold)
in cells expressing shRNA targeting LGR7 sequences starting at nucle-
otides 274 and 917 (cell lines designated L7–274 and L7–917, respec-
tively). Control THP-1 cell lines expressing 2- and 4-base pair mis-
matches of the 274 sequence (mm2 L7–274 and mm4 L7–274,
respectively) both exhibited LGR7 mRNA levels that were indistin-
guishable from that of wild type THP-1 cells (Fig. 4A). To validate target
suppression at the protein level, we performed fluorescence-activated
cytometric analysis of live cells using an LGR7 antibody targeting the
amino-terminal extracellular domain (Fig. 4B). After correcting for neg-
ative control cell surface staining, cell surface LGR7 expression in
L7–274 cells was 20% that observed in wild type THP-1 cells, whereas
LGR7 expression in L7–917 cells was 40% that of wild type THP-1 cells.
In both the mismatch L7–274 cell clones, mean LGR7 expression was
about 70% that of wild type THP-1 cell levels. Although the distribution
of the fluorescence-activated cytometric analysis data suggests that
there is still substantial overlap of surface expression levels between the
various THP-1 cell populations, these results are consistent with
shRNA-mediated suppression of mRNA expression and suggest that
the LGR7 transcript and protein expression is substantially impaired in
L7–917 and L7–274 cells and is relatively intact in the mismatch
L7–274 cell clones.
LGR7 Is Required for Relaxin-regulated Adenylate Cyclase Activation
inTHP-1Cells—Next, we examinedwhether suppressing LGR7 expres-
sion affected relaxin-stimulated adenylate cyclase activation (Fig. 5A).
To determine whether the adenylate cyclase function in L7–274 cells
was still intact, FSK and IBMX were used to stimulate intracellular
cAMP production. FSK- and IBMX-stimulated adenylate cyclase acti-
vation in L7–274 cells was indistinguishable from that generated bywild
type THP-1 cells. However, L7–274 exhibited a dramatic attenuation of
cAMP accumulation relative to wild type THP-1 cells upon stimulation
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with RLXH. L7–917 cells also exhibit a suppressed response to RLXH.
When exposed to relaxin, mm2 L7–274 cells show an intermediate
cAMP response, and mm4 L7–274 cells exhibit a response not signifi-
cantly different fromwild type THP-1 cells. This suggests that lentiviral
infection of THP-1 cells does not in itself impede their ability to respond
to relaxin and that the targeted suppression of LGR7 is likely propor-
tional to the specificity of the shRNA sequence. Together, these results
indicate that suppression of LGR7 levels in L7–274 cells blocks their
ability to respond to RLXH and that this suppressed response is specific
to relaxin since the FSK- and IBMX-induced adenylate cyclase response
remains unaffected. These data provide evidence that relaxin stimulates
cAMP accumulation in THP-1 cells through an LGR7-dependent sig-
naling pathway and that the LGR7 receptor is essential for initiating this
signal.
LGR7 Is Required for Relaxin-regulatedMigratory Potential in THP-1
Cells—To determine whether the relaxin-induced migratory response
of THP-1 cells is mediated by LGR7, we compared the migratory
responses of wild type THP-1 cells with L7–274 andmm4 L7–274 cells.
To demonstrate the chemokine-like properties of the relaxin peptide at
a more acute time point, THP-1 wild type and recombinant cells were
assessed for migratory responses to relaxin under conditions that were
more conducive for such activity. As previously established, monocytes
migrate favorably on laminin-coated transwells (64). When THP-1
migratory response was assessed at 3 h on laminin-coated transwells,
wild type cells exhibited responses to RLXH, MCP-1, and both treat-
ments which were essentially identical to those observed at 24 h on
uncoated transwells (i.e. 1.5-, 3-, and 4-fold, respectively, comparedwith
untreated) (Fig. 5B versus Fig. 2A). We observed a substantial impair-
ment of the relaxin-augmented MCP-1 chemotactic response in
L7–274 cells migrating across laminin-coated transwells that was not
observed in the mm4 L7–274 control cells (Fig. 5B). These data dem-
onstrate that the relaxin-regulated migratory responses can occur
under more acute timelines when provided with the appropriate sub-
strate and that the LGR7 signaling pathway is crucial formediating such
responses.
DISCUSSION
Intercellular communication between tissue at a site of inflammation
and distal blood cells relies on production of diffusible molecular medi-
ators. Tumor cells exist in inflammatory microenvironments because
FIGURE 3. Relaxin regulates peripheral blood
mononuclear cell biology. A, relaxin-stimulated
activation of cAMPproduction in PBMCwasmeas-
ured in cells treated with RLXH (0 and 0.0025,
0.005, 0.01, 0.02, or 0.04 ng/ml) at 37 °C for 30min.
Adenylate cyclase activation is measured as fmol
of cAMPnormalized tog ofwhole cell lysate pro-
tein. Values represent means  S.E. of 3–5 inde-
pendent experiments assayed in triplicate. Paired t
test analyses: a, versus untreated, p  0.05. B, for
measuring relaxin-stimulated adhesion of PBMC
to tissue culture treated-plastic, cellswere simulta-
neously plated and treated with RLXH (0.02
ng/ml), PMA (50 ng/ml), or untreated (vehicle
alone) and incubated at 37 °C for 24 h as described
under “Experimental Procedures.” Substrate adhe-
sion index was calculated as -fold change of
CyQuant fluorescence normalized to that of the
untreated samples of washed wells. Values repre-
sent themeans S.E. of three technical replicates.
Paired t test analysis: a, versus untreated, p 0.05.
C, to measure relaxin-stimulated migration of
PBMC, cells were seeded in the upper chamber of
24-well 5-m transwells followed immediately by
treatment with either RLXH (0.02 ng/ml), vehicle
alone (), or MCP-1 (50 ng/ml without vehicle) at
37 °C for 24 h. Cells that migrated to the lower
chamber were measured by CyQuant fluores-
cence, and the migration index was calculated as
–fold change of fluorescence normalized to the
untreated samples. Values representmeans S.E.
from six independent experiments assayed in trip-
licate. Paired t test analyses: a, versus untreated
p 0.01.
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they emulate wounds that will not heal (65). Tumor cellsmust be able to
manipulate their microenvironment to support their growth, and this
includes recruitment and functional alteration of immune cells from
surveillance toward assistance (1). In order for this to occur, tumor-
derived chemokines must first stimulate the target immune cells circu-
lating in the bloodstream. In this report, we assessed relaxin-induced
stimulation of two THP-1 cell populations by comparing acute adeny-
late cyclase responses to RLXH in non-adherent and adherent popula-
tions and found that non-adherent cells account for most of the cAMP
response to relaxin (Fig. 1B). This indicates that non-adherent cells are
the major relaxin-responsive population and suggests that once cells
have adhered, this relaxin-regulated response may no longer be
necessary.
This prompted us to examine whether relaxin can directly promote
adhesion of leukocytes and whether this might be correlated with an
enhanced migratory capacity. Here, we show that relaxin induces a 1.5-
fold enhancement inTHP-1 cell adhesion that is identical to the relaxin-
induced 1.5-fold enhanced migration and the 1.5-fold augmentation of
MCP-1-induced migration (Figs. 1C and 2, A and B). These responses
were proportional to relaxin-induced cAMP accumulation and could in
part be replicated by direct adenylate cyclase activation (Figs. 1A and
2A). We also confirmed that relaxin similarly regulates cAMP produc-
tion, adhesion, and migratory responses of PBMC (Fig. 3, A–C). Hence,
relaxin-induced migratory responses of leukocytes may be dependent
on relaxin-stimulated substrate adhesion through a cAMP-dependent
mechanism. These relatively modest changes of relaxin-regulated
migratory response are substantially quickerwhen laminin-coated tran-
swells are provided as an adhesion and migration substrate (Fig. 5B
versus 2A), suggesting that relaxin-mediated effects are substrate
dependent. It is possible that these effects could be accentuated further
in the presence of other relevant substrates.
Adhesion is an essential step required for leukocytic migration, and
modest changes to in vitro cell migration have previously been shown to
have substantial biological effects. As an example, RANKLwas shown to
induce a 1.6-fold enhancement of monocyte migration (66) and a 1.3-
fold enhancement of PBMC migration (67). This relatively modest
effect of RANKL on monocyte migration is correlated with substantial
biological relevance (68, 69). Adhesion of leukocytes to vascular endo-
thelium require several signals from chemokine-like molecules that in
turn regulate the migratory response (70). For example, MCP-1 and
interleukin-8 can each independently induce adhesion of monocytes to
vascular endothelium (71). In addition, the adhesion interaction
between leukocytes and endothelium stimulates production of leuko-
cyte-derived cytokines/chemokines, which serve to further activate the
immune response (72). This suggests that relaxin-mediated adhesion
may also modulate similar immune functions.
FIGURE 4. shRNA suppression of LGR7 expres-
sion in recombinantTHP-1cells.A, total RNAwas
extracted from THP-1 wild type, L7–274, mm2
L7–274, mm4 L7–274, and L7–917 cells under nor-
mal culture conditions. Real time PCR analysis was
performed using LGR7 and TBP primer/probe
pairs. LGR7 mRNA levels were normalized to TBP
mRNA levels, and all values are expressed relative
to parental (wt) THP-1 cells. Values represent the
means  S.E. of three independent experiments
assayed in triplicate. Paired t test analyses:a, versus
THP-1 wild type, p  0.05; b, versus THP-1 wild
type, p  0.01. B, LGR7 protein expression was
determined by flow cytometry analysis of live cells
stained with polyclonal anti-LGR7 antibody and a
secondary anti-rabbit IgG coupled to a phyco-
erythrin fluorophore. Control cells were incubated
with an anti-Akt antibody and the phycoerythrin-
coupled secondary antibody. Other controls,
unstained or stained with secondary antibody
alone, showed low background fluorescence (not
shown). A representative fluorescence-activated
cytometric analysis plot is shown. Shaded area,
THP-1wild type; solid thick line, L7-274;dashed thin
line, mm2 L7-274; dotted thin line, mm4 L7-274;
solid thin line, L7-917 cells. A representative Akt
signal inwild type cells is shown (dashed thick line).
Relative LGR7protein expression for each cell type
is calculated by internally correcting for back-
ground non specific staining of intracellular anti-
Akt antibody and expressed as the mean relative
fluorescence intensity  S.D. normalized to wild
type THP-1 cells.
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Although the current study is the first to demonstrate stimulatory
migration effects of relaxin in mononuclear leukocytes, a number of
studies have reported inhibitory functions for relaxin through a nitric
oxide-dependent pathway inmast cells (30), platelets (32), and the poly-
morphonuclear leukocytes neutrophils (37) and basophils (38).
Although relaxin has no effect on polymorphonuclear eosinophil inva-
sion of the rat cervix during pregnancy (73), other studies have reported
that relaxin positively regulates themigratory capacity of epithelial cells.
Relaxin can stimulate migration and invasion of human breast cancer
cells MCF-7 and SK-BR3 on matrigel-coated transwells (8). Similarly,
relaxin can stimulate migration of canine breast cancer cells CF33.Mt
on laminin-coated transwells, although this effect cannot be replicated
on uncoated transwells (74). Relaxin can also accelerate migration of
bronchial epithelial cells in a wound healing assay (75). Such studies
indicate that relaxin-regulatedmigratory responses are not restricted to
cells of a single lineage.
Cytokines and hormones are diffusible molecular mediator peptides
that are defined by the cells upon which they act. Chemokines were
originally defined as groups of cytokines that specifically target subsets
of blood cells for chemoattraction. It is clear now that many of these
same molecules can elicit similar chemoattraction responses in all cell
types including epithelial carcinomas (1, 76). Occasionally the distinc-
tion between a cytokine and a hormone becomes vague or redundant
since some of these can act on both cell types. The current study dem-
onstrates for the first time that the classic hormonal role for relaxin as a
regulator of epithelial and stromal functions (4) can now be expanded to
include a role in targeting blood cells as a cytokine and possibly a che-
mokine. Our data depict a unique role for relaxin in positive regulation
of cells of the immune system.
A significant enhancement ofMCP-1migratory response is observed
in the presence of relaxin in THP-1 cells and PBMC on uncoated tran-
swells and in THP-1 cells on laminin-coated transwells. This suggests
FIGURE 5. Suppression of LGR7 expression
impairs relaxin-inducedadenylate cyclase acti-
vation and migration of THP-1 cells. A, THP-1
wild type, L7–274,mm2L7–274,mm4L7–274, and
L7–917 cells were tested for cAMP responsiveness
to RLXH. Serum-starved cells were seeded into
wells of 24-well plate and left untreated (white
bars) or treated with either, mock (vehicle control)
(black bars), RLXH (0.02 ng/ml) (gray bars), or FSK
(10M) and IBMX (50M) (hatchedbars) at 37 °C for
30 min. Adenylate cyclase activation was meas-
ured as fmol of cAMP normalized to g of whole
cell lysate protein. Values represent the means 
S.E. of six independent experiments assayed in
triplicate. Paired t test analyses: a, versus respec-
tive untreated and mock, p  0.05; b, versus
respective untreated andmock, p 0.01; c, versus
L7–274 RLXH treatment, p 0.05; d, versus L7–274
RLXH treatment, p 0.01. B, impairment of relax-
in-induced migratory response by LGR7 suppres-
sion in THP-1 cells was assessed in serum-starved
cells seeded in theupper chamberof 24-well 5-m
pore transwells precoated with laminin (10
g/ml). Cells were left untreated (not shown),
treated with RLXH (0.02 ng/ml) in both chambers,
or stimulated with MCP-1 (50 ng/ml) in the lower
chamber in the absence or presence of RLXH (0.02
ng/ml) in both chambers at 37 °C for 3 h. THP-1
wild type (white bars), L7–274 (black bars), mm4
L7–274 cells (gray bars). The number of migrated
cells was determined by CyQuant fluorescence,
and the migration index was calculated as –fold
change of fluorescence compared with untreated
cells. Values represent means  S.E. of four inde-
pendent experiments assayed in triplicate. Paired t
test analyses: a, versus untreated, p 0.05; b, ver-
sus untreated, p 0.01; c, versuswtMCP-1 treated
in the lower chamber, p  0.05; d, versus L7–274
same treatment, p 0.05.
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that relaxin can rapidly activate the adhesion-dependent migratory
response under appropriate substrate conditions. This is the first dem-
onstration of relaxin-regulated migration through transwell inserts on
any cell type in less than 24 h. Furthermore, the enhanced MCP-1 reg-
ulated migratory response in the presence of relaxin is additive at all
concentrations of MCP-1 tested (Fig. 2B). Based on these results, we
suggest that by directing substrate adhesion, relaxin can augment cel-
lular response to chemoattractants such as MCP-1 at limiting concen-
trations and that relaxin may act in concert with MCP-1 and perhaps
other chemokines to enhance recruitment and infiltration of mononu-
clear cells to relaxin-producing tumor sites. Interestingly, MCP-1
expression has not been detected in prostate adenocarcinomas (77),
although its expression is substantially elevated in breast adenocarcino-
mas (78, 79). Because relaxin is expressed in both of these adenocarci-
nomas, it is possible that relaxin fulfills an MCP-1 related role in these
cancers. In themilieu of prostate and breast inflammatory tumor tissue,
relaxin is likely secreted in combination with other cytokines and che-
mokines to regulate recruitment and infiltration of the mononuclear
cells.
To verify that the relaxin receptor LGR7 is required to mediate these
relaxin-regulated biological responses in monocytes, recombinant
THP-1 cells in which LGR7 expression was suppressed were generated
by expression of interferingRNA targeting of LGR7 (Fig. 4,A andB).We
have determined that relaxin-mediated cAMP production and migra-
tory activity are dependent on LGR7 activation because both biological
responses are lost in L7–274 and intact in mismatch cell lines (Fig. 5, A
and B). From our results that the migratory response to relaxin is unaf-
fected by inhibition of protein kinase Cs, we suggest that protein kinase
C is not required to propagate this relaxin-stimulated migratory
response (Fig. 2A). The relaxin-mediated chemomigration response
and the relaxin-enhanced MCP-1 response require activation of the
G-protein coupled relaxin receptor (LGR7), and these responses can be
replicated by FSK-induced adenylate cyclase activation. This implies
that a LGR7/Gs/adenylate cyclase/cAMP pathway is necessary to reg-
ulate the relaxin-induced migratory response.
Although further studies are required to examine the role of relaxin in
leukocyte extravasation and infiltration of the tumor, the current study
does show that relaxin has a definitive role in recruitment of leukocytes.
Because tumor-infiltrating leukocytes often promote cancer in response
to chemokinetic factors derived from the tumor itself, the presence of a
relaxin gradient emanating from a tumor site may be an indicator of a
poor prognosis for cancer patients. To provide molecular targets for
selective inhibitors and activators, future studieswill require elucidation
of specific fate commitment and differentiation pathways induced by
relaxin.
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